Buller A L, Larson H C, Schneider B E, Beaton J A, Morrisett R A, Monaghan D T
Department of Pharmacology, University of Nebraska Medical Center, Omaha 68198-6260.
J Neurosci. 1994 Sep;14(9):5471-84. doi: 10.1523/JNEUROSCI.14-09-05471.1994.
The relationship between four pharmacologically distinct NMDA receptor subtypes, identified in radioligand binding studies, and the recently identified NMDA receptor subunits (NR1a-g, NR2A-D) has not been determined. In this report, we demonstrate that the anatomical distribution of the four NMDA receptor subtypes strikingly parallels the distribution of mRNA encoding NR2A-D subunits. The distribution of NR2A mRNA was very similar to that of "antagonist-preferring" NMDA receptors [defined by high-affinity 3H-2-carboxypiperazine-4-yl-propyl-1-phosphonic (3H-CPP) binding sites; correlation coefficient = 0.88]. Agonist-preferring NMDA receptors localized to brain regions expressing both NR2B mRNA and NR1- mRNA (NR1 splice variant lacking insert 1). NR2C mRNA was largely restricted to the cerebellar granule cell layer, a region that displays a unique pharmacological profile. NR2D mRNA localized exclusively to those diencephalic nuclei that have a fourth, distinct pharmacological profile (typified by the midline thalamic nuclei). The pharmacology of native NMDA receptors was compared to that of heteromeric NMDA receptors expressed in Xenopus oocytes (NR1/NR2A, NR1/NR2B, NR1/NR2C). The oocyte-expressed NR1/NR2A receptor displayed a higher affinity for antagonists and a slightly lower affinity for agonists than the NR1/NR2B receptor. These patterns are analogous to those found for radioligand binding to native receptors in the lateral thalamus and medial striatum, respectively. NMDA receptors in the lateral thalamus (with a high density of NR2A subunit mRNA) displayed higher affinity for antagonists and a lower affinity for agonists than did NMDA receptors of the medial striatum (a region rich in NR2B mRNA). Relative to the NR1/NR2A and NR1/NR2B receptors, oocyte-expressed NR1/NR2C receptors had a lower affinity specifically for both D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid (D-CPPene) and homoquinolinate (HQ). This pattern was identical to that observed for cerebellar (NR2C-containing) versus forebrain (NR2A- and NR2B-containing) NMDA receptors. Taken together, the data in this report suggest that the four previously identified native NMDA receptor subtypes differ in their NR2 composition. Furthermore, the NR2 subunits significantly contribute to the anatomical and pharmacological diversity of NMDA receptor subtypes.
在放射性配体结合研究中鉴定出的四种药理学特性不同的NMDA受体亚型与最近鉴定出的NMDA受体亚基(NR1a - g、NR2A - D)之间的关系尚未确定。在本报告中,我们证明这四种NMDA受体亚型的解剖学分布与编码NR2A - D亚基的mRNA的分布显著平行。NR2A mRNA的分布与“拮抗剂偏好型”NMDA受体(由高亲和力的3H - 2 - 羧基哌嗪 - 4 - 基 - 丙基 - 1 - 膦酸(3H - CPP)结合位点定义)的分布非常相似;相关系数 = 0.88。拮抗剂偏好型NMDA受体定位于同时表达NR2B mRNA和NR1 - mRNA(缺少插入片段1的NR1剪接变体)的脑区。NR2C mRNA主要局限于小脑颗粒细胞层,该区域表现出独特的药理学特征。NR2D mRNA仅定位于那些具有第四种独特药理学特征的间脑核(以中线丘脑核为代表)。将天然NMDA受体的药理学与非洲爪蟾卵母细胞中表达的异源NMDA受体(NR1/NR2A、NR1/NR2B、NR1/NR2C)的药理学进行了比较。卵母细胞表达的NR1/NR2A受体与NR1/NR2B受体相比,对拮抗剂具有更高的亲和力,对激动剂的亲和力略低。这些模式分别类似于在外侧丘脑和内侧纹状体中放射性配体与天然受体结合所发现的模式。外侧丘脑(NR2A亚基mRNA密度高)中的NMDA受体与内侧纹状体(富含NR2B mRNA的区域)中的NMDA受体相比,对拮抗剂具有更高的亲和力,对激动剂的亲和力更低。相对于NR1/NR2A和NR1/NR2B受体,卵母细胞表达的NR1/NR2C受体对D - 3 - (2 - 羧基哌嗪 - 4 - 基)- 1 - 丙烯基 - 1 - 膦酸(D - CPPene)和高喹啉酸(HQ)均具有较低的亲和力。这种模式与在小脑(含NR2C)与前脑(含NR2A和NR2B)的NMDA受体中观察到的模式相同。综上所述,本报告中的数据表明,先前鉴定出的四种天然NMDA受体亚型在其NR2组成上存在差异。此外,NR2亚基对NMDA受体亚型的解剖学和药理学多样性有显著贡献。